Followers | 2543 |
Posts | 250732 |
Boards Moderated | 34 |
Alias Born | 05/06/2014 |
Thursday, June 01, 2017 1:49:35 AM
Source: GlobeNewswire Inc.
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) and BIOMM SA (BVMF:BIOM3) today announced that they have entered into a supply and distribution agreement for the commercialization of Afrezza® (insulin human) Inhalation Powder in Brazil. Under the supply and distribution agreement, Biomm will be responsible for preparing and filing the necessary applications for regulatory approval of Afrezza, including from the Agência Nacional de Vigilância Sanitária and, with respect to pricing matters, from the Camara de Regulação de Mercado de Medicamentos. Upon satisfactory approval from these regulatory bodies, MannKind will manufacture and supply Afrezza to Biomm, and Biomm will be responsible for promoting and distributing Afrezza within Brazil.
“We are pleased to partner with Biomm to bring Afrezza to the Brazilian diabetes market,” said Michael Castagna, Chief Executive Officer of MannKind Corporation. “Our founder, Alfred Mann, had a vision to reduce the global burden of diabetes through novel technologies. In 2015, more than 14 million people were estimated to have diabetes in Brazil. Given Biomm’s presence and knowledge of the diabetes market in Brazil, we believe that Biomm is the ideal partner to reach healthcare providers and patients with the message that there is another potential option in their fight against diabetes.”
“As a pioneering biotechnology company in Brazil, we believe that we can leverage our current portfolio of diabetes products to offer another option to the significant and growing numbers of patients with diabetes,” said Heraldo Marchezini, Diretor Presidente/CEO of Biomm SA. “We are proud to be the first company to bring inhaled mealtime insulin to the Brazilian market.”
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
ABOUT BIOMM SA
Biomm SA company (BOVESPA:BIOM3) is the First Brazilian Biopharmaceutical Company and the only human biotech company listed on the Brazilian BOVESPA Stock Exchange. The company is committed to making difficult to treat chronic diseases more cost effective, thereby improving the quality of life for patients. With innovation in its DNA, Biomm is pioneer in biotechnology and in the production of insulin in Brazil.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding MannKind's ability to directly commercialize pharmaceutical products. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the ability to obtain regulatory approvals, the ability to get satisfactory pricing terms from regulators and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
MannKind Contact:
Rose Alinaya
Acting CFO
661-775-5300
ralinaya@mannkindcorp.com
Biomm SA Contact:
c/o RMA Comunicação
Alethéia Rocha - + 55 (11) 2244-5972| 96443 -7638
aletheia.rocha@rmacomunicacao.com.br
Monica Permagnani - + 55 (11) 2244 – 5985| 94187 - 6025
monica.permagnani@rmacomunicacao.com.br
Primary Logo
Recent MNKD News
- MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update • GlobeNewswire Inc. • 05/08/2024 08:18:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:11:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:05:42 PM
- MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease • GlobeNewswire Inc. • 05/06/2024 10:05:00 AM
- MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024 • GlobeNewswire Inc. • 05/01/2024 08:00:00 PM
- MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases • GlobeNewswire Inc. • 04/30/2024 10:05:00 AM
- MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease • GlobeNewswire Inc. • 04/29/2024 10:05:00 AM
- MannKind Repays Certain Debt Obligations • GlobeNewswire Inc. • 04/03/2024 10:00:00 AM
- MannKind Announces CFO Transition • GlobeNewswire Inc. • 03/26/2024 08:05:00 PM
- INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps • GlobeNewswire Inc. • 03/11/2024 10:05:00 AM
- MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8 • GlobeNewswire Inc. • 03/05/2024 11:05:00 AM
- MannKind Corporation Announces Participation at Upcoming Conferences • GlobeNewswire Inc. • 03/04/2024 06:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:05:20 PM
- MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update • GlobeNewswire Inc. • 02/27/2024 09:00:00 PM
- MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024 • GlobeNewswire Inc. • 02/20/2024 11:00:00 AM
- MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza® • GlobeNewswire Inc. • 02/15/2024 11:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 11:06:28 AM
- MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million • GlobeNewswire Inc. • 01/02/2024 11:05:00 AM
- MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 12/28/2023 11:00:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM